Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $44.56.

BCYC has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Oppenheimer reissued an “outperform” rating and issued a $48.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a report on Thursday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a research note on Monday, September 16th.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the sale, the chief executive officer now owns 380,864 shares of the company’s stock, valued at approximately $8,478,032.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 4,584 shares of company stock worth $102,040. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP raised its position in Bicycle Therapeutics by 176.1% in the first quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock worth $123,076,000 after acquiring an additional 3,152,433 shares during the period. Armistice Capital LLC increased its stake in shares of Bicycle Therapeutics by 17.9% in the 2nd quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock worth $39,913,000 after purchasing an additional 300,000 shares in the last quarter. First Light Asset Management LLC raised its holdings in Bicycle Therapeutics by 16.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock worth $28,028,000 after purchasing an additional 191,717 shares during the period. Westfield Capital Management Co. LP lifted its position in Bicycle Therapeutics by 13.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock valued at $25,869,000 after purchasing an additional 121,613 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Bicycle Therapeutics by 0.6% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock valued at $17,975,000 after purchasing an additional 4,976 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Trading Down 0.2 %

BCYC opened at $24.73 on Friday. The stock has a market cap of $1.06 billion, a PE ratio of -5.56 and a beta of 0.89. The business has a 50 day moving average of $24.06 and a 200-day moving average of $23.07. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $28.67. The company has a quick ratio of 14.77, a current ratio of 14.77 and a debt-to-equity ratio of 0.01.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Tuesday, August 6th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.33. The firm had revenue of $9.36 million for the quarter, compared to analysts’ expectations of $6.13 million. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. The business’s revenue for the quarter was down 17.9% on a year-over-year basis. Equities research analysts predict that Bicycle Therapeutics will post -3.17 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.